Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL692078 | 0.94 | EPHX1 (0.52) | EPHX1EPHX2HTTPRMT1CA1 | |
| SCHEMBL10062059 | 0.89 | EPHX1 (0.61) | EPHX1EPHX2PRMT1MEN1USP2 | |
| SCHEMBL194006 | 0.88 | ALDH1A1 (0.52) | EPHX1EPHX2HTTPRMT1MEN1 | |
| SCHEMBL4572740 | 0.86 | EPHX1 (0.56) | EPHX1EPHX2HTTPRMT1CA1 | |
| SCHEMBL31455527 | 0.83 | EPHX1 (0.61) | EPHX1EPHX2PRMT1CA1CA2 | |
| SCHEMBL31455546 | 0.83 | EPHX1 (0.61) | EPHX1EPHX2PRMT1CA1CA2 | |
| SCHEMBL6824758 | 0.83 | EPHX1 (0.61) | EPHX1EPHX2PRMT1CA1CA2 | |
| SCHEMBL17379956 | 0.83 | EPHX1 (0.61) | EPHX1EPHX2PRMT1CA1CA2 | |
| SCHEMBL9424811 | 0.82 | EPHX1 (0.68) | EPHX1MEN1KMT2A | |
| SCHEMBL3076338 | 0.82 | EPHX1 (0.71) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4171489-B1 | SANITIZING COMPOSITION | UNILEVER IP HOLDINGS B V (NL) | 2026-03-25 | — | — | EP | claimed |
| US-20230255868-A1 | SANITIZING COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2023-08-17 | — | — | US | claimed |
| EP-4171489-A1 | SANITIZING COMPOSITION | Unilever IP Holdings B.V. (NL) | 2023-05-03 | — | — | EP | claimed |
| CN-115734808-A | Disinfecting compositions | 联合利华知识产权控股有限公司 | 2023-03-03 | — | — | CN | claimed |
| WO-2022002882-A1 | SANITIZING COMPOSITION | UNILEVER IP HOLDINGS B.V. (NL) | 2022-01-06 | — | — | WO | claimed |
| WO-2001089591-A2 | SURFACE-TREATED SUPERABSORBENT POLYMER PARTICLES | BASF AKTIENGESELLSCHAFT (DE) | 2001-11-29 | — | — | WO | claimed |
| US-20260090969-A1 | COMPOSITIONS THAT PROTECT CELLS FROM OXIDATIVE AND MITOCHONDRIAL STRESS | Nuchido Limited (GB) | 2026-04-02 | — | — | US | disclosed |
| EP-4171489-B1 | SANITIZING COMPOSITION | UNILEVER IP HOLDINGS B V (NL) | 2026-03-25 | — | — | EP | disclosed |
| EP-4547213-B1 | ANTI-ACNE COMPOSITION | UNILEVER IP HOLDINGS B V (NL) | 2026-01-14 | — | — | EP | disclosed |
| US-20250375363-A1 | ANTI-ACNE COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250243143-A1 | 1,3-Fatty Diol Compounds And Derivatives Thereof | AGAIN BIO APS (DK) | 2025-07-31 | — | — | US | disclosed |
| WO-2025149314-A1 | TOPICAL SKIN COMPOSITION | UNILEVER IP HOLDINGS B.V. (NL) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025149337-A1 | TOPICAL SKIN IMPROVEMENT COMPOSITION | UNILEVER IP HOLDINGS B.V. (NL) | 2025-07-17 | — | — | WO | disclosed |
| US-20050186231-A1 | Stabilization with substituted ureas against color degradation of personal care products | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2001089591-A2 | SURFACE-TREATED SUPERABSORBENT POLYMER PARTICLES | BASF AKTIENGESELLSCHAFT (DE) | 2001-11-29 | — | — | WO | disclosed |
| EP-0654511-B1 | Ink and ink jet recording method and apparatus using the same | CANON KK (JP) | 2001-06-20 | — | — | EP | disclosed |
| EP-0569864-B1 | Ink, ink-jet recording process making use of the ink, and equipment therefor | CANON KK (JP) | 1995-10-18 | — | — | EP | disclosed |
| EP-0654511-A1 | Ink and ink jet recording method and apparatus using the same | CANON KABUSHIKI KAISHA (JP) | 1995-05-24 | — | — | EP | disclosed |
| US-5354369-A | Containing hydroxyalkyl-substituted urea, 2-oxo-oxazolidine and dye or pigment; free of feathering or bronze phenomenon | CANON KABUSHIKI KAISHA (JP) | 1994-10-11 | — | — | US | disclosed |
| EP-0569864-A1 | Ink, ink-jet recording process making use of the ink, and equipment therefor | CANON KABUSHIKI KAISHA (JP) | 1993-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375363-A1 | ANTI-ACNE COMPOSITION | EBP, CUTA, LPO | EPHX1 2624/4885EPHX2 3068/4885HTT 728/4885 |
| US-20260090969-A1 | COMPOSITIONS THAT PROTECT CELLS FROM OXIDATIVE AND MITOCHONDRIAL STRESS | NLN, TFAM, CYP27B1 | EPHX1 3865/4885EPHX2 4534/4885HTT 3444/4885 |
| US-20250243143-A1 | 1,3-Fatty Diol Compounds And Derivatives Thereof | DGAT1, DGAT2, DSG1 | EPHX1 219/4885EPHX2 303/4885HTT 2626/4885 |
| US-20050186231-A1 | Stabilization with substituted ureas against color degradation of personal care products | CUTA, PUF60, USP10 | EPHX1 1957/4885EPHX2 843/4885HTT 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.